Tradestie Institutional Equity Comparison Engine

IDEV vs MEDX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MEDX Overall Edge

MEDX Captures Institutional Edge (1โ€“1 Pillars ยท 2โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Horizon Kinetics Medical ETF (MEDX) driven by superior Momentum & Technical while IDEV counters with relative strength in Options & Structure. Fundamentally, IDEV trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus MEDX at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, IDEV sits in UNCLASSIFIED (11th %ile IV; Dealer Gamma Walls on Pro) against MEDX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
IDEV N/M vs MEDX N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner MEDX
1Y +8.6% vs +18.6% ยท 52W Pos 65% vs 87%
Options & Structure Winner IDEV
UNCLASSIFIED (11th %ile IV) vs UNCLASSIFIED (N/A IV)
IDEV NYSE Arca
iShares Core MSCI International Developed Markets ETF
Institutional Equity
$88.40
-1.43% 1D
Market Cap N/A
1M Return -1.2%
1Y Return +8.6%
Forward P/E N/M
Unified AI Score
56.4 / 100 HOLD
Tech 48.0 Fund 50.0 Flow 50.0 Mom 58.9
MEDX NASDAQ
Horizon Kinetics Medical ETF
Institutional Equity
$37.66
-0.92% 1D
Market Cap N/A
1M Return +4.61%
1Y Return +18.61%
Forward P/E N/M
Unified AI Score
42.6 / 100 HOLD
Tech 42.0 Fund 45.0 Flow 50.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IDEV +8.6% MEDX +18.61% Spread: +6.73 pp (MEDX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IDEV TTM Op. Margin: N/A MEDX TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IDEV vs MEDX. Trailing 12-month operating profitability (IDEV N/A vs MEDX N/A) and valuation multiples (IDEV N/M vs MEDX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IDEV (1) vs MEDX (2)
Institutional Metric IDEV MEDX Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 65% ($78โ€“$94) 87% ($32โ€“$39) Stronger Trend MEDX
Beta / 30D Volatility Risk Regime 0.94ฮฒ ยท 19% Vol 0.34ฮฒ ยท 19% Vol Lower Realized Risk MEDX
Unified Institutional Score Composite Signal 56.4 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite IDEV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IDEV vs MEDX Buy Guide
IDEV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live IDEV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MEDX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MEDX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IDEV nor MEDX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.